智通财经APP获悉，香港联交所最新资料显示，7月24日，易方达基金减持泰格医药(03347)27.31万股， 每股作价50.0506港元，总金额约为1366.88万港元。减持后最新持股数目为1351.47万股，持股比例为 10.98%。 ...

Core Viewpoint - Tiger Medical (300347.SZ) announced that its major shareholder, director, and general manager, Ms. Cao Xiaochun, plans to reduce her shareholding in the company [1] Group 1 - Ms. Cao Xiaochun holds 51,661,774 shares, representing 6.0413% of the company's total share capital after excluding repurchased shares, and 7.0575% of the total A-share capital [1] - The planned reduction will not exceed 3 million shares, which accounts for 0.3508% of the company's total share capital after excluding repurchased shares, and 0.4098% of the total A-share capital [1] - The reduction is set to occur within three months after a 15 trading day period following the announcement, during which no shares will be sold [1]

Core Viewpoint - The performance of Zhang Fusheng, a fund manager at the Fortune Fund, has significantly declined, particularly in the Fortune Clean Energy Industry Mixed A Fund, which has recorded a return of -37.91% over his tenure of 3 years and 60 days, raising concerns among investors about his management capabilities [2][5][7]. Fund Performance Summary - The Fortune Clean Energy Industry Mixed A Fund was established with an initial size of 17.51 billion yuan but has seen a reduction in net assets to 8.55 billion yuan as of June 30, 2025, reflecting a decrease of 14.19% [23][43]. - The fund's performance metrics show a year-to-date return of -3.45%, a 3-month return of -1.06%, and a 1-year return of 2.38%, with a 2-year return of -28.05% and a 3-year return of -49.66% [7][5]. - The fund's unit net value as of July 25, 2025, is 1.0043, with an overall return since inception of 18.11% [7]. Fund Manager Background - Zhang Fusheng has a diverse background in finance, having worked at Deloitte, China International Capital Corporation, and Gao Hua Securities before joining Fortune Fund in November 2021 [3][2]. - He has managed several funds, including the Fortune Value Growth Mixed Fund and the Fortune Automotive Smart Selection Mixed Fund, but his overall performance has been underwhelming, with the Fortune Automotive Smart Selection Mixed A Fund showing a return of -21.76% over 2 years and 301 days [5][25]. Investor Sentiment - Investors have expressed dissatisfaction with the fund's performance, with complaints highlighting significant losses, including a reported 48.16% decline for long-term holders [14][10]. - The high turnover rate of the fund, reaching 490.76% in Q2 2023, indicates frequent trading, which may contribute to increased volatility and costs, further impacting investor confidence [29][28].

關於全資子公司購買日本MICRON部分股權 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 HANGZHOU TIGERMED CONSULTING CO., LTD. 杭州泰格醫藥科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：3347） 自願性公告 本 公 告 由 杭 州 泰 格 醫 藥 科 技 股 份 有 限 公 司（「本公司」）自 願 刊 發，藉 以 知 會 本 公 司 股 東 及 潛 在 投 資 者 有 關 本 公 司 的 最 新 業 務 發 展。 本 公 司 董 事 會（「董事會」）欣 然 宣 佈，本 公 司 全 資 附 屬 公 司 株 式 會 社 泰 格 醫 藥 日 本（「日本泰格」）與 日 本MICRON╱株 式 會 社 マ イ ク ロ ン（「MICRON」） 原 股 東 簽 署《股 份 轉 讓 協 ...

Group 1 - The innovation drug ETF (560900) has seen a rise of 2.64% with a trading volume of 14.26 million yuan, indicating active market participation [1] - The CSI Innovation Drug Industry Index (931152) increased by 2.86%, with notable gains from stocks such as Jiuzhou Pharmaceutical (603456) up 9.17%, Tigermed (300347) up 8.60%, and WuXi AppTec (603259) up 6.70% [1] - As of July 28, the latest scale of the innovation drug ETF reached 61.85 million yuan, with a total of 62.97 million shares, both marking a six-month high [1] Group 2 - The National Healthcare Security Administration announced that the 11th batch of centralized procurement will optimize specific rules, moving away from solely relying on the lowest bid, which is expected to alleviate excessive competition in the pharmaceutical industry [2] - Domestic CRO and CDMO sectors are benefiting from the global recovery of innovative drugs, with leading companies like WuXi AppTec and WuXi Biologics reporting strong mid-year performance [2] - The CSI Innovation Drug Industry Index reflects the overall performance of up to 50 representative listed companies involved in innovative drug research and development [2]

Group 1 - The core viewpoint of the news is that Tiger Medical has signed a share transfer agreement to acquire a portion of MICRON's shares, resulting in Tiger Medical Japan holding 56.37% of MICRON's equity after the transaction [1][2] - The purchase price for the shares is 484 million Japanese yen, equivalent to approximately 23.48 million Chinese yuan [1] - MICRON, established in 2005 and headquartered in Tokyo, specializes in medical imaging and clinical trial services, and has built a strong reputation in Japan's clinical research field [1][2] Group 2 - MICRON's core business focuses on imaging analysis, serving both domestic and international pharmaceutical companies, along with other related services such as clinical monitoring and medical imaging diagnostic software [2] - The acquisition is expected to enhance the company's business expansion in Japan and the Asia-Pacific region by leveraging MICRON's established market presence and customer resources [2] - The collaboration is anticipated to facilitate deep integration of technology and talent, thereby strengthening the overall competitiveness in medical imaging and clinical services [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 HANGZHOU TIGERMED CONSULTING CO., LTD. 杭州泰格醫藥科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） 承董事會命 杭州泰格醫藥科技股份有限公司 董事長 葉小平 香 港，2025年7月28日 於 本 公 告 日 期，執 行 董 事 為 葉 小 平 博 士、曹 曉 春 女 士、吳 灝 先 生 及 聞增玉先生；獨立非執行董事為廖啟宇先生、袁華剛先生及劉毓文女士。 （股 份 代 號：3347） 海外監管公告 本 公 告 乃 杭 州 泰 格 醫 藥 科 技 股 份 有 限 公 司（「本公司」）根 據 香 港 聯 合 交 易 所有限公司證券上市規則第13.10B條 而 作 出。 茲 載 列 本 公 司 於 深 圳 證 券 交 易 所 網 站 刊 登 公 告 如 下 ...

Core Viewpoint - Tiger Medical (300347) announced that its wholly-owned subsidiary, Tiger Medical Japan, has signed a share transfer agreement with the original shareholders of MICRON to acquire a portion of MICRON's shares, resulting in Tiger Medical Japan holding 56.37% of MICRON's shares after the transfer [1] Company Summary - MICRON was established in 2005 and is headquartered in Tokyo, Japan, with over 160 employees. It specializes in medical imaging and clinical trial services as a CRO (Contract Research Organization) [1] - As of May 31, 2025, MICRON's total assets are 781 million JPY, while its net assets are -452 million JPY. For the period from January to May 2025, MICRON reported a revenue of 940 million JPY and a net loss of 67.04 million JPY [1]

（股 份 代 號：3347） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 HANGZHOU TIGERMED CONSULTING CO., LTD. 自願性公告 關於全資子公司購買日本MICRON部分股權 杭州泰格醫藥科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） MICRON截 至2025年5月31日總資產78,094.76萬 日 元，淨 資 產-45,175.17萬 日 元；2025年1–5月主營業務收入93,959.78萬 日 元，淨 利 潤-6,704.74萬 日 元。 （以 上 數 據 未 經 審 計）。 一、股份購買概述 – 2 – 本 公 告 由 杭 州 泰 格 醫 藥 科 技 股 份 有 限 公 司（「本公司」）自 願 刊 發，藉 以 知 會 本 公 司 股 東 及 潛 在 投 資 者 有 關 本 公 司 的 最 ...

智通财经7月28日电，泰格医药(300347.SZ)公告称，公司持股5%以上股东、董事及总经理曹晓春计划自 公告披露之日起15个交易日之后的3个月内，以集中竞价和/或大宗交易方式减持公司股份不超过300万 股，占剔除回购专户股份数后公司总股本的0.3508%，占公司A股总股本的0.4098%。减持原因为偿还债 务及利息，降低质押融资风险。 泰格医药：持股5%以上股东曹晓春拟减持不超过300万股 ...